Christine Blank
DEA tightens fentanyl scheduling
Due to the increased use of illicit fentanyl mixed with heroin and used in counterfeit prescription drugs, the DEA placed all illicit fentanyl analogues not already regulated by the Controlled Substances Act into Schedule I.
Opioid prescription limits gain support
A pharmacist organization is among the supporters of a new Medicare Part D proposal, which calls for a 7-day supply limit on opioid prescriptions.
FDA issues new warning on liver disease drug
FDA is adding a Boxed Warning, its most prominent warning, on a liver disease medicine.
Combo UTI drug can now treat costly pneumonias
FDA approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of ceftazidime and avibactam (Avycaz) to include 2 types of pneumonia.
Radioactive drug for digestive cancer snags FDA approval
FDA approved a new drug to treat a type of cancer that affects the pancreas or gastrointestinal tract.
Cannabis-derived epilepsy drug on the horizon
A pharmaceutical formulation of purified cannabidiol, a cannabinoid without euphoric side effects, is expected to launch in the second half of this year.
Blindness gene therapy price tag stirs controversy
A patient advocacy group is criticizing the hefty price tag of a new treatment for blindness.
Survey uncovers lupus corticosteroid treatment issues
Patients with systemic lupus erythematosus often self-manage their corticosteroid medication without the consent of their healthcare providers, according to a recent multicountry survey.
FDA approves first drug for breast cancer with BRCA gene
FDA approved the first drug to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation.
FDA takes tough stance on kids’ opioid cold meds
FDA is taking its toughest stance yet on opioid-containing cough and cold medications for children.